TRENDING :  Market Movers  |  Top 50   SPY (0.2%)    IWM (-0.3%)    XTN (0.15%)    UNP (4.36%)    UGAZ (-2.25%)    TYME (-6.18%)    RYAAY (0.83%)    PANW (-1.66%)    PAGS (-9.74%)    ORCL (0.08%)    MU (0.58%)    MHK (0.69%)    M (0.49%)    GOOGL (0.11%)    GDXJ (-2.03%)    FB (-0.28%)    EWZ (1.03%)    EWW (-0.11%)    CRM (0.42%)    CGC (4%)    BABA (-0.33%)    BA (0.68%)    ATVI (0.74%)    ARCW (-4.94%)    APC (0.24%)

 NVS - Novartis AG

$76.41 [-0.9][-1.16%]

Next Earnings



Trade Idea »


No recommendations found.

This list is limited to recommendations made in last 7 days only. Subscribe to a service to see all their recommendations.


Service NameTrader% Success
Big PortfolioTraderCZ100.00 %Subscribe
cerevisiologyJohn Cho20.00 %Follow


Roche's (RHHBY) Q1 Sales Strong on Solid Demand for New Drugs

Roche Holding AG RHHBY posted strong sales for the first quarter of 2019 propelled by demand for new drugs amid biosimilar competition for legacy drugs Consequently the company raised its guidance for the year 160 Roche s stock has gained 8 in the past six months against the industry

Health Care Sector Update for 04/17/2019: IONS,NVS,MASI,TXMD,ONCS

Top Health Care StocksTop Health Care Stocks JNJ 0 61 JNJ 0 61 PFE 2 46 PFE 2 46 ABT 4 58 ABT 4 58 MRK 4 56 MRK 4 56 AMGN 2 84 AMGN 2 84 Health care stocks were ending near their session lows including a more than 2 5 slump for the NYSE Health Care Index in recent trade Shares

Here's Why Ionis Pharmaceuticals Slumped Today

What happened Shares of Ionis Pharmaceuticals NASDAQ IONS are down 13 at 12 45 p m EDT without any direct news from the biotech However there were a couple of indirect news items from competitors and collaborators that seem to have investors taking profits on Ionis

Marijuana ETF Down 9% in Past Month: Time to Enter the Space?

Marijuana ETF picked up this year on growing acceptance The pure play fund ETFMG Alternative Harvest ETF MJ rose about 35 9 year to date as of Apr 15 but started skidding from late March The fund in fact has lost about 9 in the past month Particularly the fund lost about 3 4

Radius Health (RDUS) Rallies 33.4% YTD on Robust Tymlos Sales

Shares of Radius Health Inc RDUS have gained 35 3 in the year so far outperforming the industry s growth of 12 4 The company primarily focuses on the development of endocrine therapeutics in the areas of osteoporosis and oncology 160 Radius Health got a significant

Alnylam Initiates Phase III ILLUMINATE-B Study on Lumasiran

Alnylam Pharmaceuticals Inc 160 ALNY 160 announced that it has initiated ILLUMINATE B a global phase III pediatric study on its investigational subcutaneously administered RNAi 160 therapeutic lumasiran The drug is being evaluated for the treatment of primary hyperoxaluria type

Allergan Falls as Supreme Court Dismisses Restasis Litigation

Allergan plc s AGN shares declined almost 1 presumably due to the U S Supreme Court s unfavorable ruling in a litigation related to patents covering its blockbuster eye drug Restasis 160 per an article posted on Reuters In October last year a Texas federal district court

Novartis' (NVS) BLA for Ophthalmology Drug Accepted by FDA

Novartis AG NVS announced that the FDA accepted its Biologics License Application BLA for ophthalmology candidate brolucizumab RTH258 Novartis is seeking FDA approval of the candidate for the treatment of wet age related macular degeneration AMD also known as neovascular AMD or

Alnylam (ALNY) Reports Phase III ENVISION Data on Givosiran

Alnylam Pharmaceuticals Inc ALNY announced positive complete results from the ENVISION phase III study of givosiran an investigational RNAi therapeutic targeting aminolevulinic acid synthase 1 ALAS1 for the treatment of acute hepatic porphyria AHP In the study givosiran met the

Ophthotech Gets Rights to Gene Therapy for BEST Disease

Ophthotech Corporation OPHT 160 announced that it has obtained development commercialization rights to AAV gene therapy program for BEST1 related retinal diseases from the University of Pennsylvania Penn and the University of Florida Research Foundation UFRF In October Ophthotech

Pharma Stock Roundup: AZN, MRK, GSK Get Regulatory Approvals, Sandoz Inks New Deal

This was a relatively light week in terms of news in the pharma sector ahead of the first quarter earnings season While Glaxo GSK gained FDA approval for a new two drug HIV medicine for previously untreated patients AstraZeneca AZN Merck s MRK PARP inhibitor Lynparza was approved for

Novartis to Market Rizmoic Through Sandoz, Spins Off Alcon

Novartis AG s NVS generic arm Sandoz signed an agreement with Japanese pharmaceutical company Shionogi amp Co Ltd for commercialization of Rizmoic in the key European markets of Germany the U K and the Netherlands plus right of first refusal for certain other European

Biotechnology Market on a Tear: 5 ETFs in Spotlight

The biotech industry has kept its promise for solid returns so far The rally in some major biotechnology indexes reflects the same In this context the NASDAQ Biotechnology Index has returned 17 6 year to date Following the trend S amp P Biotechnology Select Industry Index has

Top Research Reports for McDonald's, Enterprise Products & Charles Schwab

Thursday April 11 2019 The Zacks Research Daily presents the best research output of our analyst team Today s Research Daily features new research reports on 16 major stocks including McDonald s MCD Enterprise Products Partners EPD and Charles Schwab SCHW These research

Intercept Reports Additional Positive Data From NASH Study

Intercept Pharmaceuticals Inc ICPT announced positive additional supportive data from its pivotal phase III REGENERATE study of obeticholic acid OCA in patients with liver fibrosis due to nonalcoholic steatohepatitis NASH NASH is a serious progressive liver disease caused by excessive